Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
The last decade has witnessed a tremendous progress in the acute therapy of migraine, with sumatriptan, belonging to a new class of drugs, now known as 5-HT(1B/1D/1F) receptor agonists, leading the way. The undoubted success of sumatriptan stimulated the development of new triptans as well as other suitable pharmacological tools and experimental models to probe into complex migraine mechanisms. In this review, we discuss the main experimental models for migraine, against the background of the disease pathophysiology and 5-HT receptors considered most important for migraine therapy. We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium.
De Vries
P
P
Department of Pharmacology, and Cardiovascular Research Institute (COEUR), Erasmus University Medical Centre Rotterdam, The Netherlands.
Villalón
C M
CM
Saxena
P R
PR
D000818:Animals; D004195:Disease Models, Animal; D005544:Forecasting; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D008954:Models, Biological; D011985:Receptors, Serotonin / Q000145:classification / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D018170:Sumatriptan / Q000627:therapeutic use
D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D018170:Sumatriptan